Holen Sie sich die Stockscreener-App
59.82
2.47%
1.44
Handel nachbörslich:
59.82
Schlusskurs vom Vortag:
$58.38
Offen:
$57.78
24-Stunden-Volumen:
1.02M
Relative Volume:
0.74
Marktkapitalisierung:
$8.61B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-766.63M
KGV:
-10.49
EPS:
-5.7051
Netto-Cashflow:
$-712.55M
1W Leistung:
+8.84%
1M Leistung:
+0.89%
6M Leistung:
+45.16%
1J Leistung:
+89.30%
1-Tages-Spanne:
$57.47
$59.98
1-Wochen-Bereich:
$55.97
$59.98
52-Wochen-Spanne:
$27.66
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
59.82 | 8.40B | 0 | -766.63M | -712.55M | -5.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Bestätigt | Needham | Buy |
| 2025-09-12 | Eingeleitet | Goldman | Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Aberdeen Group plc Increases Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX SEC FilingsVaxcyte, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PCVX Should I Buy - Intellectia AI
PCVX.O Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Sell Alert: Jim Wassil Sells 2,250 Shares of Vaxcyte Inc (PCVX) - gurufocus.com
Vaxcyte (PCVX) COO sells 2,250 shares in planned Rule 10b5-1 trades - Stock Titan
James Wassil sells 7,395 PCVX shares (NASDAQ: PCVX) - Stock Titan
Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Ideas: Is now the right time to enter Vaxcyte Inc2026 Short Interest & Trade Opportunity Analysis Reports - baoquankhu1.vn
(PCVX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Vaxcyte joins elite club of stocks with RS ratings over 90 - msn.com
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener
Certain Pre-funded warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com
Certain Restricted Stock Units of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener
Should Vaxcyte’s (PCVX) Fully Enrolled VAX-31 Phase 3 Trials Prompt a Portfolio Reassessment? - simplywall.st
Vanguard disaggregates holdings; PCVX ownership shown as 0 (PCVX) - stocktitan.net
Portfolio Update: Can Vaxcyte Inc continue delivering strong returns2026 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn
Assenagon Asset Management S.A. Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO - Law360
Vaxcyte completes enrollment in two Phase 3 trials for VAX-31 - Investing.com Canada
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - Investing News Network
Vaxcyte (PCVX) Completes Enrollment for Key Phase 3 Trials - GuruFocus
Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative - simplywall.st
Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet - simplywall.st
Responsive Playbooks and the PCVX Inflection - Stock Traders Daily
Vaxcyte Announces Significant Development of First-of-Its-Kind PCV31 - Drug Topics
PCVX PE Ratio & Valuation, Is PCVX Overvalued - Intellectia AI
JPMorgan Chase & Co. Acquires 366,266 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc.: Fundamental Analysis and Financial Ratings | 1PCVX | US92243G1085 - marketscreener.com
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet - Investing.com Australia
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCVX) - GuruFocus
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCV - GuruFocus
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Advances VAX-31 Vaccine with Positive Study Resul - gurufocus.com
Vaxcyte (NASDAQ:PCVX) CAO Sells $105,138.44 in Stock - MarketBeat
Vaxcyte (PCVX) Price Target Decreased by 17.52% to 83.49 - MSN
Vaxcyte : March Investor Presentation (6862ba) - MarketScreener
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate - The Manila Times
Vaxcyte Advances VAX-31 into Phase 3 Clinical Program Following Positive Phase 1/2 Study Results in Older Adults - quiverquant.com
Vaxcyte publishes positive Vax-31 phase 1/2 adult study results in The Lancet Infectious Diseases - marketscreener.com
A 31-strain pneumonia shot showed strong immune responses in adults 50+ - Stock Titan
Vaxcyte SVP, finance & CAO Cowan sells $105k in stock - Investing.com UK
Vaxcyte Publishes Positive Vax-31 Phase 1/2 Adult Study Results In The Lancet Infectious Diseases - TradingView
Positive VAX-31 Phase 1/2 Adult Data Published in The - GlobeNewswire
Vaxcyte (PCVX) finance SVP sells 1,892 shares under 10b5-1 plan - Stock Titan
Vaxcyte Completes $632.5 Million Public Offering of Common Stock - Global Legal Chronicle
Elvia Cowan sells shares; RSU vesting at PCVX (NASDAQ: PCVX) - Stock Titan
Forecast Cut: Is Vaxcyte Inc affected by consumer sentimentPortfolio Return Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):